MENU
+Compare
OCX
Stock ticker: NASDAQ
AS OF
Dec 18, 04:59 PM (EDT)
Price
$2.23
Change
+$0.02 (+0.90%)
Capitalization
24.2M

OCX Oncocyte Corp Forecast, Technical & Fundamental Analysis

a developer of ovel, non-invasive, liquid biopsy diagnostics for the early detection of cancer

OCX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for OCX with price predictions
Dec 17, 2024

OCX's RSI Oscillator is staying in oversold zone for 1 day

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 75 cases where OCX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OCX advanced for three days, in of 201 cases, the price rose further within the following month. The odds of a continued upward trend are .

OCX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for OCX turned negative on December 16, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OCX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for OCX entered a downward trend on December 16, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.658) is normal, around the industry mean (23.300). P/E Ratio (4.558) is within average values for comparable stocks, (83.485). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (14.451) is also within normal values, averaging (43.338).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. OCX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OCX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.

View a ticker or compare two or three
OCX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a developer of ovel, non-invasive, liquid biopsy diagnostics for the early detection of cancer

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
15 Cushing
Phone
+1 949 409-7600
Employees
76
Web
https://www.oncocyte.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HOFV1.050.04
+3.96%
Hall of Fame Resort & Entertainment Company
BLDR160.12-0.45
-0.28%
Builders FirstSource
NEWP1.39-0.01
-0.71%
New Pacific Metals Corp
ITGR136.68-1.69
-1.22%
Integer Holdings Corp
WOLF7.85-0.15
-1.88%
Wolfspeed

OCX and Stocks

Correlation & Price change

A.I.dvisor tells us that OCX and FATE have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OCX and FATE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCX
1D Price
Change %
OCX100%
-0.45%
FATE - OCX
31%
Poorly correlated
-6.00%
VNRX - OCX
30%
Poorly correlated
-5.15%
GOSS - OCX
29%
Poorly correlated
+1.71%
BMRN - OCX
29%
Poorly correlated
+2.52%
CRIS - OCX
28%
Poorly correlated
-0.86%
More